What ICU medications should a new ICU nurse learn, including their mechanisms of action, indications, contraindications, and administration guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Essential ICU Medications for New Nurses

As a new ICU nurse, you must master approximately 15-20 core medications across four critical categories: vasopressors/inotropes, sedatives/analgesics, paralytics, and resuscitation fluids—prioritizing those that directly impact mortality and hemodynamic stability.

1. VASOPRESSORS & INOTROPES (Highest Priority)

Norepinephrine (Levophed)

  • MOA: Alpha-1 and beta-1 adrenergic agonist causing vasoconstriction and increased cardiac contractility
  • Indications: First-line vasopressor for septic shock and vasodilatory shock 1
  • Dosing: Start 0.01-0.05 mcg/kg/min, titrate to MAP ≥65 mmHg 1
  • Administration: Central line preferred; can use peripheral temporarily with close monitoring
  • Contraindications: Relative—avoid as sole agent in hypovolemia without concurrent fluid resuscitation
  • Key Monitoring: MAP, heart rate, peripheral perfusion, urine output, arterial line strongly recommended 1

Epinephrine (Adrenaline)

  • MOA: Non-selective alpha and beta agonist (vasoconstriction + inotropy + chronotropy)
  • Indications: Second-line when additional agent needed beyond norepinephrine; cardiac arrest 1
  • Dosing: 0.01-0.5 mcg/kg/min IV infusion; 1 mg IV push for cardiac arrest
  • Administration: Central line only for infusions
  • Contraindications: Use cautiously with tachyarrhythmias
  • Key Monitoring: Continuous ECG, blood glucose (causes hyperglycemia), lactate levels 2

Vasopressin (Pitressin)

  • MOA: V1 receptor agonist causing vasoconstriction via non-adrenergic pathway
  • Indications: Adjunct to norepinephrine to raise MAP or decrease norepinephrine dose 1
  • Dosing: Fixed dose 0.03-0.04 units/min (NOT titrated) 1
  • Administration: Central or peripheral line
  • Contraindications: Do NOT use as single initial vasopressor; avoid doses >0.04 units/min except salvage 1
  • Key Monitoring: Skin perfusion (risk of digital/mesenteric ischemia), sodium levels

Dopamine

  • MOA: Dose-dependent: low dose (DA receptors), mid dose (beta-1), high dose (alpha-1)
  • Indications: Alternative to norepinephrine ONLY in highly selected patients with bradycardia and low arrhythmia risk 1
  • Dosing: 2-20 mcg/kg/min
  • Administration: Central line preferred
  • Contraindications: Tachyarrhythmias, pheochromocytoma
  • Critical Pitfall: Do NOT use for "renal protection"—this is debunked 1

Dobutamine

  • MOA: Selective beta-1 agonist increasing cardiac contractility
  • Indications: Low cardiac output states, cardiogenic shock
  • Dosing: 2.5-20 mcg/kg/min 1
  • Administration: Central line preferred
  • Contraindications: Hypovolemia (correct first), severe hypotension without concurrent vasopressor
  • Key Monitoring: Blood pressure (can cause vasodilation), cardiac output if available

Phenylephrine (Neo-Synephrine)

  • MOA: Pure alpha-1 agonist (vasoconstriction only, no cardiac effects)
  • Indications: Very limited—only when norepinephrine causes serious arrhythmias, high cardiac output with low BP, or salvage therapy 1
  • Dosing: 0.5-3 mcg/kg/min
  • Administration: Central or peripheral line
  • Contraindications: Most septic shock scenarios (not recommended as routine) 1

2. SEDATIVES (Critical for Ventilated Patients)

Propofol (Diprivan)

  • MOA: GABA agonist causing rapid sedation/hypnosis
  • Indications: Short-term sedation, patients requiring frequent neurologic assessments 3
  • Dosing:
    • Loading: 5 mcg/kg/min over 5 min (only if hemodynamically stable) 3
    • Maintenance: 5-50 mcg/kg/min 3
  • Administration: Central line preferred (causes pain/phlebitis in peripheral); use dedicated line
  • Contraindications: Egg/soy allergy, hemodynamic instability
  • Critical Adverse Effects:
    • Hypotension (most common)
    • Propofol-related infusion syndrome (PRIS): monitor triglycerides, avoid >48-72 hours at high doses
    • Respiratory depression 3
  • Key Monitoring: Triglycerides (risk pancreatitis), sedation depth (RASS/SAS), blood pressure

Dexmedetomidine (Precedex)

  • MOA: Alpha-2 agonist causing sedation without respiratory depression
  • Indications: Preferred over benzodiazepines for mechanically ventilated patients; reduces delirium 3
  • Dosing:
    • Loading: 1 mcg/kg over 10 min (AVOID in hemodynamically unstable) 3
    • Maintenance: 0.2-0.7 mcg/kg/hr (can increase to 1.5 mcg/kg/hr) 3
  • Administration: Central or peripheral line
  • Contraindications: Severe bradycardia, heart block
  • Adverse Effects: Bradycardia, hypotension, hypertension with loading dose 3
  • Key Advantage: Patients arousable and cooperative; preserves respiratory drive

Midazolam (Versed)

  • MOA: Benzodiazepine (GABA agonist)
  • Indications: Short-term sedation only (<48 hours); alcohol/benzodiazepine withdrawal 3
  • Dosing:
    • Loading: 0.01-0.05 mg/kg over several minutes 3
    • Maintenance: 0.02-0.1 mg/kg/hr 3
  • Administration: Central or peripheral line
  • Contraindications: Prolonged use (accumulation), severe respiratory depression
  • Critical Pitfall: Associated with increased delirium, prolonged ventilation, worse outcomes—avoid for long-term sedation 3
  • Key Monitoring: Sedation depth, respiratory status

Lorazepam (Ativan)

  • MOA: Benzodiazepine (GABA agonist)
  • Indications: Previously used for long-term sedation; now limited use due to propylene glycol toxicity 3
  • Dosing:
    • Loading: 0.02-0.04 mg/kg (≤2 mg) 3
    • Maintenance: 0.02-0.06 mg/kg q2-6hr PRN or 0.01-0.1 mg/kg/hr (≤10 mg/hr) 3
  • Administration: Central or peripheral line
  • Contraindications: Prolonged high-dose infusions
  • Critical Adverse Effect: Propylene glycol toxicity (metabolic acidosis, nephrotoxicity) with prolonged infusions 3
  • Current Practice: Largely replaced by propofol/dexmedetomidine

3. ANALGESICS (Pain Management Priority)

Fentanyl

  • MOA: Mu-opioid receptor agonist
  • Indications: First-line IV opioid for non-neuropathic pain 4, 3, 4
  • Dosing:
    • Bolus: 25-100 mcg IV q5-15min PRN
    • Infusion: 25-200 mcg/hr
  • Administration: Central or peripheral line
  • Contraindications: Severe respiratory depression, paralytic ileus
  • Advantages: Rapid onset, no active metabolites, hemodynamically stable
  • Key Monitoring: Pain scores (CPOT/BPS for nonverbal patients), respiratory rate, sedation level 3

Morphine

  • MOA: Mu-opioid receptor agonist
  • Indications: Alternative IV opioid for pain 4
  • Dosing: 2-5 mg IV q2-4hr PRN; infusion 2-30 mg/hr
  • Administration: Central or peripheral line
  • Contraindications: Renal failure (active metabolites accumulate), hemodynamic instability
  • Adverse Effects: Histamine release (hypotension, bronchospasm), active metabolites prolong effects
  • Key Monitoring: Pain scores, blood pressure, renal function

Hydromorphone (Dilaudid)

  • MOA: Mu-opioid receptor agonist
  • Indications: Alternative IV opioid, especially with morphine allergy 4
  • Dosing: 0.2-1 mg IV q2-4hr PRN; infusion 0.5-3 mg/hr
  • Administration: Central or peripheral line
  • Note: 5-7x more potent than morphine
  • Key Monitoring: Pain scores, respiratory status

Ketamine (Adjunct)

  • MOA: NMDA receptor antagonist
  • Indications: Low-dose adjunct to reduce opioid consumption in post-surgical ICU patients 4
  • Dosing: 1-2 mcg/kg/hr (low-dose infusion) 4
  • Administration: Central or peripheral line
  • Contraindications: Severe hypertension, increased ICP (relative)
  • Adverse Effects: Emergence reactions, delirium, hypertension
  • Key Advantage: Opioid-sparing, preserves respiratory drive

4. NEUROMUSCULAR BLOCKING AGENTS (Paralytics)

Cisatracurium (Nimbex)

  • MOA: Non-depolarizing neuromuscular blocker (competitive acetylcholine antagonist)
  • Indications: Severe ARDS, refractory ventilator dyssynchrony, status epilepticus
  • Dosing:
    • Loading: 0.15-0.2 mg/kg IV
    • Maintenance: 1-3 mcg/kg/min 5
  • Administration: Central line preferred
  • Advantages: Hoffman elimination (organ-independent), no histamine release
  • Critical Requirements:
    • Patient MUST be adequately sedated and analgesed BEFORE paralysis 5
    • Train-of-four monitoring mandatory
    • Daily sedation holidays to assess neurologic function
  • Key Monitoring: Train-of-four (goal 1-2 twitches), sedation depth (BIS/EEG if available) 5

Rocuronium (Zemuron)

  • MOA: Non-depolarizing neuromuscular blocker
  • Indications: Rapid sequence intubation, short procedures
  • Dosing:
    • RSI: 0.6-1.2 mg/kg IV push
    • Maintenance: 0.1-0.2 mg/kg q20-30min or 8-12 mcg/kg/min infusion
  • Administration: Central or peripheral line
  • Advantage: Rapid onset (60-90 seconds)
  • Reversal: Sugammadex available for rapid reversal
  • Key Monitoring: Train-of-four, adequate sedation/analgesia

Vecuronium (Norcuron)

  • MOA: Non-depolarizing neuromuscular blocker
  • Indications: Alternative paralytic for intubation/procedures
  • Dosing:
    • Loading: 0.08-0.1 mg/kg IV
    • Maintenance: 0.01-0.015 mg/kg q30-60min or 0.8-1.2 mcg/kg/min infusion
  • Administration: Central or peripheral line
  • Contraindications: Hepatic/renal dysfunction (prolonged duration)
  • Key Monitoring: Train-of-four, liver/kidney function

Succinylcholine (Anectine)

  • MOA: Depolarizing neuromuscular blocker
  • Indications: Emergency rapid sequence intubation ONLY (fastest onset)
  • Dosing: 1-1.5 mg/kg IV push (single dose only)
  • Administration: Central or peripheral line
  • Contraindications:
    • Hyperkalemia (can cause cardiac arrest)
    • Burns >24 hours old
    • Crush injuries
    • Prolonged immobilization
    • Malignant hyperthermia history
    • Neuromuscular disease
  • Critical Adverse Effects: Hyperkalemia, malignant hyperthermia, bradycardia
  • Key Monitoring: Potassium level pre-administration, continuous ECG

5. RESUSCITATION FLUIDS

Crystalloids (0.9% Saline or Balanced Solutions)

  • MOA: Volume expansion via intravascular and interstitial distribution
  • Indications: First-line for septic shock resuscitation 1
  • Dosing: Initial bolus ≥30 mL/kg for sepsis-induced hypoperfusion 1
  • Administration: Peripheral or central line
  • Guideline Recommendation: Crystalloids are fluid of choice; balanced crystalloids or saline equally acceptable 1
  • Key Monitoring: Hemodynamic response (MAP, pulse pressure variation, stroke volume variation), fluid overload signs

Albumin 5%

  • MOA: Colloid providing oncotic pressure and volume expansion
  • Indications: Adjunct when patients require substantial crystalloids in septic shock 1
  • Dosing: Variable, typically 250-500 mL boluses
  • Administration: Peripheral or central line
  • Guideline Recommendation: Weak recommendation as adjunct to crystalloids 1
  • Contraindications: Avoid hydroxyethyl starches (strong recommendation against) 1

CRITICAL NURSING PRINCIPLES

Sedation/Analgesia Strategy

Treat pain FIRST before sedation 4. The 2018 guidelines emphasize analgesia-first approach:

  • Assess pain routinely with validated tools (CPOT/BPS for nonverbal patients) 3
  • Administer analgesics before sedatives
  • Target light sedation (RASS -1 to 0) unless contraindicated 3
  • Use non-benzodiazepine sedatives (propofol/dexmedetomidine) preferentially 3
  • Implement daily sedation interruption protocols 3

Vasopressor Management

  • Norepinephrine is first-line for septic shock 1
  • Target MAP ≥65 mmHg initially 1
  • Add vasopressin (0.03 units/min) or epinephrine as second agent 1
  • Arterial line placement strongly recommended for all patients on vasopressors 1
  • Administer vasopressors simultaneously with fluid resuscitation—do NOT delay for "adequate filling" 2

Paralytic Safety

  • Never paralyze without adequate sedation and analgesia 5
  • Use train-of-four monitoring (goal 1-2 twitches) 5
  • Consider BIS/EEG monitoring for sedation depth in paralyzed patients 5
  • Daily assessment for continued need
  • Increased risk of ICU-acquired weakness with prolonged use

Common Pitfalls to Avoid

  1. Dopamine for "renal protection": Completely ineffective, do not use 1
  2. Benzodiazepines for prolonged sedation: Associated with delirium, worse outcomes 3
  3. Propofol >48-72 hours without monitoring triglycerides: Risk of PRIS 3
  4. Phenylephrine as routine vasopressor: Not recommended in septic shock 1
  5. Lorazepam infusions >24-48 hours: Propylene glycol toxicity 3
  6. Paralysis without adequate sedation: Awareness and psychological trauma 5
  7. Vasopressin titration: Fixed dose only, never titrate 1

References

2
Research

Vasopressor Therapy in the Intensive Care Unit.

Seminars in respiratory and critical care medicine, 2021

Related Questions

In a 21-year-old female runner who developed leg pain and progressively spreading bruising, what urgent evaluation and management are indicated?
As a 22‑year‑old, how can I obtain a Do‑Not‑Resuscitate (DNR) order and what are the eligibility criteria?
In a 19‑year‑old female with a three‑month history of progressive right‑temporal headache aggravated by coughing, cold exposure, bright light, and fan airflow, now accompanied by right‑sided painful ophthalmoplegia (intermittent diplopia that resolves when one eye is covered, medial deviation of the right eye, right upper‑eyelid ptosis, and retro‑orbital pain) and no fever or other systemic signs, what is the most likely diagnosis and what urgent investigations and initial management are recommended?
What is the appropriate evaluation and initial management for a 19‑year‑old male with severe unexplained weight loss?
What is the recommended initial treatment for a patient with orthopnea requiring two pillows and grade 2 peripheral edema?
Should an elderly woman with elevated TSH and normal T3 and T4 be started on low‑dose levothyroxine?
What is the correct reconstitution and dilution procedure for Micafungin (intravenous) administration?
How should I manage a patient on ciprofloxacin who develops leukopenia and lymphadenopathy?
In a 65-year-old man with end-stage renal disease on peritoneal dialysis, heart failure, and diabetes, is the regimen of metolazone 10 mg daily, spironolactone 25 mg daily, and torsemide 20 mg twice daily appropriate?
Which patient population is most at risk for Enterococcus urinary tract infection?
How should I manage an elderly female patient on 100 µg levothyroxine daily who has an elevated TSH of 7.28 mIU/L with normal T3 and T4?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question